Jpmorgan Chase & CO Oncocyte Corp Transaction History

Jpmorgan Chase & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.25 - $15.6 $1,176 - $73,382	-4,704 Reduced 60.25%	3,104 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.76 - $15.98 $1,098 - $23,107	1,446 Added 22.73%	7,808 $6,000
Q2 2022 Aug 11, 2022	SELL	$0.86 - $1.53 $28,854 - $51,334	-33,552 Reduced 84.06%	6,362 $6,000
Q1 2022 May 11, 2022	BUY	$1.15 - $2.25 $9,186 - $17,973	7,988 Added 25.02%	39,914 $59,000
Q4 2021 Feb 10, 2022	BUY	$2.04 - $3.59 $16,587 - $29,190	8,131 Added 34.17%	31,926 $69,000
Q3 2021 Nov 12, 2021	BUY	$3.53 - $5.89 $83,996 - $140,152	23,795 New	23,795 $85,000

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $246M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.